This article was originally published in The Gray Sheet
Executive SummaryReceives clearance from FDA to market the Seitzinger Tripolar cutting forceps, the firm announces Aug. 9. Designed "to replace more expensive stapling devices" in procedures such as hysterectomies, gall bladder removal, appendectomies and other gynecological and general surgical procedures, the device "enables the surgeon to cauterize tissue to reduce or eliminate bleeding, while activating a cutting knife allowing the tissue to be transected in a one-handed operation." The firm maintains that "in addition to the savings from not using any staples, the operating time can be reduced by as much as one third" with use of the device
You may also be interested in...
Draft policy moots crowdfunding for high-cost rare diseases alongside financial support for those "amenable to one-time treatment" but falls way short of some patient groups' expectations.
India’s Hilleman Laboratories says it’s aiming to develop an affordable vaccine that will target pregnant women in low- and middle-income countries to prevent Group B Streptococcus, a potentially fatal infection passed to babies during childbirth.
Chi-Med’s surufatinib has come up trumps in a second trial in neuroendocrine tumors, after the monitoring committee recommended an early halt following achievement of its PFS target in the pancreatic setting.